| AZ | EN | RU

STATISTICS


CARDIOVASCULAR PATHOLOGY IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
Gasimova F.N., Babayeva L.K., Atakishiyeva V.N., Guliyeva I.M., Mammadov M.Y.

DOI: 10.61775/2413-3302.v2i36.02

SUMMARY
The article deals with the peculiarities of cardiovascular pathology in patients with ANCA associated vasculitis (AAV), where special attention is paid to the mechanism of its formation and its influence on the clinical prognosis of patients. The author analyses the data on the frequency of cardiovascular diseases in patients with this type of vasculitis and emphasises that vascular inflammation and chronic inflammatory process may contribute to accelerated development of atherosclerosis and increased risk of cardiovascular complications in these patients. The article points out the importance of cardiovascular risk factors in the treatment of patients with AAV and the need for an integrated approach in the diagnosis and therapy of these patients to improve their quality of life and to predict the outcomes of the disease.
Keywords: ANCA associated vasculitis, vascular inflammation, cardiac lesions, complications

REFERENCES
  1. Almaani S., Fussner L.A., Brodsky S. et al. ANCA-Associated Vasculitis: An Update // J Clin Med., 2021;10 (7):1446. doi: 10.3390/jcm10071446.
  2. Kronbichler A., Leierer J., Gauckler P., Shin J.I. Comorbidities in ANCA-associated vasculitis // Rheumatology (Oxford). 2020;59(Suppl 3): i79-i3. doi:10. 1093/rheumatology/kez617.
  3. Mercuzot C., Letertre S., Daien C.I. et al. Comorbidities and health-related quality of life in patients with Antineutrophil Cytoplasmic Antibody (ANCA) – associated vasculitis // Autoimmun Rev., 2021; 20(1):102708. doi: 10.1016/j.autrev.2020. 102708.
  4. Söderberg D, Segelmark M. Neutrophil extracellular traps in ANCA-associated vasculitis Front // Immunol., 7 (2016), p. 256, doi: 10.3389/fimmu.2016.00256.
  5. Floyd L., Morris A.D., Woywodt A., Dhaygude A. Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat? // Clin Kidney J., 2022;15(4):618-623. doi:10.1093/ckj/sfac009.
  6. Wallace Z.S., Fu X., Harkness T., Stone J.H. et al. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type // Rheumatology, 59 (9) (2020), pp. 2308-2315. doi:10.1093/rheumatology/kez589.
  7. Massicotte-Azarniouch D., Petrcich W., Walsh M. et al. Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study // Clin Kidney J, 15 (4) (2021), pp. 681-692. doi: 10.1093/ckj/sfab229.
  8. Kitching A.R., Anders H.J., Basu N. et al. ANCA‐associated vasculitis // Nat Rev Dis Prim [Internet]. 2020;6(1):71. doi: 10.1038/s41572-020-0204-y.
  9. Goyal A., Qayyum Abbasi H., Mashkoor Y. et al. Assessment of cardiovascular risk in patients with ANCA-associated vasculitis: A systematic review and meta-analysis // International Journal of Cardiology Cardiovascular Risk and Prevention, 2024, Vol. 23, 200334. doi: 10.1016/j.ijcrp.2024.200334.
  10. Borowiec A., Dąbrowski R. Kowalik I. et al. Elevated levels of D-dimer are associated with inflammation and disease activity rather than risk of venous thromboembolism in patients with granulomatosis with polyangiitis in long term observation // Adv. Med. Sci., 2020; 65 (1) pp. 97-101. doi: 10.1016/j.advms.2019. 12.007.
  11. Sun G, Yafasova A, Baslund B, et al. Long-term risk of heart failure and other adverse cardiovascular outcomes in granulomatosis with polyangiitis: A Nationwide Cohort study // J Rheumatol. 2022;49(3):291-298. doi:10.3899/ jrheum.210677.
  12. Guillevin L., Cohen P., Gayraud M. et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients // Medicine, 1999;78:26-37.
  13. Guillevin L., Durand-Gasselin B., Cevallos R. et al. Microscopic polyangitis: clinical and laboratory findings in eighty-five patients // Arthritis Rheum., 1999; 42:421-30.
  14. Reinhold-Keller E., Buege N, Latza U. et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis // Arthritis Rheum., 2000; 43:1021-32.
  15. Hazebroek M.R., Kemna M.J., Schalla S. et al. Prevalence and prognostic relevance of cardiac involvement in ANCA-associated vasculitis: eosinophilic granulomatosis with polyangitis and granulomatosis with polyangiitis // Int J Cardiol., 2015; 199:170-179.
  16. Guillevin L., Lhote F., Gayraud M. et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients // Medicine, 1996; 75:17-28, 15.
  17. Malgorzata Potentas-Policewicz, Justyna Fijolek Granulomatosis with polyangiitis: clinical characteristics and updates in diagnosis // Front. Med., 2024; Sec. Pulm. Medicine, 2024; Vol. 11: 1369233. doi:10.3389/ fmed.2024. 1369233.
  18. Miszalski-Jamka T, Szczeklik W, Sokolowska B. et al. Cardiac involvement in Wegener’s granulomatosis resistant to induction therapy // Eur Radiol., 2011;21: 2297–304. doi: 10.1007/s00330-011-2203-6.
  19. Morelli S., Gurgo Di Castelmenardo A.M, Conti F., Sgreccia A. et al. Cardiac involvement in patients with Wegener’s granulomatosis // Rheumatol Int., 2000;19: 209–12. doi: 10.1007/s002960000059.
  20. Oliveira G.H., Seward J.B, Tsang T.S, Specks U. Echocardiographic findings in patients with Wegener granulomatosis // Mayo Clin Proc., 2005; 80:1435–40. doi: 10.4065/80.11.1435.
  21. McGeoch L., Carette S. Cuthbertson D, et al. Cardiac involvement in granulomatosis with polyangiitis // J Rheumatol., 2015;42(7):1209‐1212. doi: 10.3899/jrheum.141513.
  22. Florian A, Slavich M, Blockmans D, Dymarkowski S, Bogaert J. Cardiac involvement in granulomatosis with polyangiitis (Wegener granulomatosis) // Circulation, 2011;124: e342–4.
  23. Miłkowska-Dymanowska J., LaskowskaP., Rzuczkowski M. et al. Untypical Manifestations of Granulomatosis with Polyangiitis - A Review of the Literature // SN Comprehensive Clinical Medicine, 2019; 1:616–626. doi:10.1007/s42399-019-00083-4.
  24. Marques N, Mimoso J, Bohorquez R, Lázaro M, Brito H, Pereira MA, Valente I, Mendonça I, Gomes V. Unstable angina as initial manifestation of Wegener granulomatosis: case report // Rev Port Cardiol. 2008 Nov;27(11):1469-77. English, Portuguese. PMID: 19227813.
  25. Lazarus M.N, Khurana R, Sethi AS, Naughton MA. Wegener’s granulomatosis presenting with an acute ST-elevation myocardial infarct (STEMI) // Rheumatology, 2006; 45:916–8.
  26. Miloslavsky E., Unizony S. The heart in vasculitis // Rheum Dis Clin North Am, 2014; 40: 11–26. doi: 10.1016/j.rdc.2013.10.006.
  27. Silveira L.H. Cardiovascular manifestations of systemic vasculitides // Curr Rheumatol Rep., 2020; 22(10):72. doi: 10.1007/s11926-020-00952-1.
  28. Байрашевская А.В., Дегтярева Н.Д., Раденска-Лоповок С.Г. АНЦА-ассоциированные васкулиты // Архив патологи, 2022;84(1):50–58. doi: 10.17116/patol20228401150.
  29. Martinez F., Chung J.H, Digumarthy S.R, Kanne J.P, et al. Common and uncommon manifestations of Wegener granulomatosis at chest CT: radiologic-pathologic correlation // Radio Graphics, 2011; 32:51–69.
  30. Cocco G, Gasparyan AY. Myocardial ischemia in Wegener’s granulomatosis: coronary atherosclerosis versus vasculitis // Open Cardiov. Med J. 2010; 4:57–62.
  31. Lim H.E, Lee Y.H, Ahn J.C. Wegener's granulomatosis with progressive conduction disturbances and atrial fibrillation // Heart, 2007;93:777. doi: 10.1136/ hrt.2006.090530.
  32. Goodfield N.E, Bhandari S., Plant W.D. et al. Cardiac involvement in Wegener’s granulomatosis // Br Heart J. 1995; 73:110–5.
  33. Valente F., Rozen L., Carlier S., Godart P. An uncommon case of complete AV block // BMC Cardiov. Disord., 2022;22:429. doi: 10.1186/s12872-022-02866-5.
  34. Emmi G., Bettiol A., Gelain E. et al. Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis // Nat Rev Rheumatol., 2023;19: 378–393. doi:10.1038/s41584-023-00958-w
  35. Furuta S., Iwamoto T., Nakajima H. Update on eosinophilic granulomatosis with polyangiitis // Allergol. Int., 2019;68(4):430-436. doi: 10.1016/j.alit.2019.06.004.
  36. Bond M., Fagni F., Moretti M. et al. At the heart of eosinophilic granulomatosis with polyangiitis: into cardiac and vascular involvement // Curr Rheumatol Rep., 2022;24(11):337‐351. doi: 10.1007/s11926-022-01087-1.
  37. Alexandra Villa-Forte, Brian F. Mandell Cardiovascular Disorders and Rheumatic Disease // Revista Española de Cardiología, 2011; Vol. 64, Issue 9, p. 809-817. doi: 10.1016/j.rec.2011.05.013
  38. Anaev E.Kh., Belevskiy A.S., Kniajeskaia N.P. Eosinophilic granulomatosis with polyangiitis: etiopathogenesis, classification and clinical phenotypes // Pulmonologiya, 2023; 33(3): 393–400. DOI: 10.18093/0869-0189-2022-4101.
  39. Knockaert D.C. Cardiac involvement in systemic inflammatory diseases // Eur. Heart J. 2007; 28 (15): 1797–1804. DOI: 10.1093/ eurheartj/ehm193.
  40. Sinico R.A., Di Toma L., Maggiore U. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome // Arthritis Rheum., 2005;52:2926-35. doi: 10.1002/art. 21250.
  41. Mavrogeni S., Karabela G., Gialafos E. et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance // Inflamm. Allergy Drug Targets, 2013; 12(5):322-327. doi: 10.2174/ 18715281113129990054.
  42. Sinico R.A., Di Toma L., Maggiore U. et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome // Arthritis Rheum., 2005;52:2926-35. doi: 10.1002/art. 21250.
  43. Mavrogeni S., Karabela G., Gialafos E. et al. Cardiac involvement in ANCA (+) and ANCA (-) Churg-Strauss syndrome evaluated by cardiovascular magnetic resonance // Inflamm. Allergy Drug Targets, 2013; 12(5):322-327. doi: 10.2174/ 18715281113129990054.
  44. Ribi C., Cohen P., Pagnoux C. et al. Treatment of Churg-Strauss syndrome without poor- prognosis factors: multicenter, prospective, randomized, open-label study of seventy-two patients // Arthritis Rheum., 2008;58(2):586-94. doi: 10.1002/art.23198.
  45. Bourgarit A., Le Toumelin P., Pagnoux C. et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients // Medicine, 2005; 84(5):323-30. doi: 10.1097/01. md.0000180793.80212.17.
  46. Терапия по Сесилю: в 4 т. Т. ІІІ / под ред. Л. Голдмана, Э. Шафера - Москва: ГЭОТАР-Медиа, 2023; 1184. с. doi: 10.33029/978-5-9704-7003-9-GCM-2023-1-1184.
  47. Ahn J. K. Clinical features and outcome of microscopic polyangiitis under a new consensus algorithm of ANCA-associated vasculitis in Korea / J. K. Ahn [et al.] // Rheumatology international, 2011; Vol. 32, №10: Р. 2979–2986.
  48. Mavrogeni S., Manoussakis M.N., Karagiorga T.C. Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides //Arthritis Rheum., 2009 Aug 15;61(8):1121-9. doi: 10.1002/art.24695.
  49. Katarzyna Życińska, Anna Borowiec Cardiac manifestations in antineutrophil cytoplasmic autoantibody (ANCA) — associated vasculitides // Kardiologia Polska, 2016; 74, 12: 1470–1476; DOI: 10.5603/KP.a2016.0138.